© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
November 02, 2021
Underlying autoimmune disease alters uveitis therapy.
October 26, 2021
XIPERE, the first therapy utilizing the suprachoroidal space, demonstrates rapid efficacy, durable benefit, and favorable safety profile.
October 12, 2021
Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
September 13, 2021
Anterior uveitis therapy offers anti-inflammatory effect after dosing is stopped.
September 09, 2021
Quan Dong Nguyen, MD, MSc, FARVO, FASRS, speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.
August 31, 2021
Study examines immunomodulatory as a potential long-term treatment option.
August 09, 2021
Long-term sustained-release therapy pays off in management of chronic, vision-threatening disease.
July 03, 2021
While operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.
June 17, 2021
Measures of inflammation can predict treatment outcomes for patients
June 11, 2021
Standardization of Uveitis Nomenclature (SUN) Working Group utilized machine learning to create new uveitis classification criteria, inciting hope for implementation in clinical and research settings.